Related Experiment Video
Updated: Feb 14, 2026

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications
Published on: October 7, 2016
Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis
Nengpan Zhang1, Chunlin Li2, Dayong Zhou3
1School of Nano Technology and Nano Bionics, University of Science and Technology of China, Hefei 230026, China; CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
Insights
Targeted thrombolysis using cyclic RGD (cRGD) functionalized liposomes improved urokinase efficacy. These liposomes bind activated platelets, enhancing drug delivery and reducing dosage by 75% for effective thrombosis treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Pharmacology
Background:
- Thrombosis is a major cause of morbidity and mortality, often treated with thrombolytic drugs.
- Current thrombolytic therapies have limitations including short plasma half-life and systemic side effects.
- Urokinase is a widely used thrombolytic agent, but its clinical efficacy can be improved.
Purpose of the Study:
- To develop and evaluate cyclic RGD (cRGD) functionalized liposomes for targeted delivery of urokinase.
- To enhance thrombolytic efficacy and reduce systemic side effects of urokinase.
- To investigate the binding specificity and drug release characteristics of cRGD-urokinase liposomes.
Main Methods:
- Preparation of cRGD functionalized liposomes encapsulating urokinase.
- Flow cytometry to assess binding of cRGD liposomes to activated platelets.
- In vitro release studies to determine urokinase release kinetics.
- In vitro and in vivo thrombolysis experiments using a mouse mesenteric thrombosis model.
Main Results:
- cRGD liposomes specifically bind to activated platelets, not resting platelets.
- Urokinase release from liposomes reached a plateau around 5 hours with 60% release.
- In vitro experiments showed good thrombolysis potential for cRGD-urokinase liposomes.
- In vivo studies demonstrated a 75% dose reduction of urokinase with equivalent thrombolytic effect compared to free urokinase.
- cRGD liposomes improved thrombolytic efficacy by approximately 4-fold over free urokinase.
Conclusions:
- cRGD functionalized liposomes offer a promising strategy for targeted thrombolysis.
- Encapsulating urokinase in cRGD liposomes enhances its therapeutic efficacy and reduces required dosage.
- This targeted drug delivery system holds significant potential for clinical application in treating thrombosis.
Abstract:
Thrombosis, a critical event in blood vessels, not only is associated with myocardial infarction and stroke, but also accounts for considerable morbidity and mortality. Thrombolytic drugs are usually applied to the treatment of acute myocardial infarction, acute cerebral infarction and pulmonary embolism. However, thrombolytic drugs show limited efficacy in clinical practice because of the short half-life in plasma and systemic side effects. In this study, the cyclic RGD (cRGD) functionalized liposomes were prepared to encapsulate urokinase, a cheap and widely used thrombolytic drug in clinic and better thrombolysis efficacy was achieved. The flow cytometry analysis showed that the cRGD liposomes could bind to the activated platelets while not to the resting platelets. In vitro release study revealed that the release percentage reached plateau in about 5 h with 60% urokinase being released from liposomes. Results from the in vitro thrombolysis experiments demonstrated a good thrombolysis potential of the cRGD urokinase liposomes. The in vivo thrombolysis study demonstrated that the cRGD liposomes could significantly reduce the dose of urokinase by 75% while achieving the equivalent thrombolysis effect as the free urokinase in mouse mesenteric thrombosis model. In conclusion, the cRGD liposomes encapsulating urokinase hold great promise in clinic for better thrombolytic efficacy.
Statement Of Significance:
In this paper, the cRGD liposomes were prepared to encapsulate urokinase for targeted thrombolysis therapy. The cRGD liposomes could specifically bind to the activated platelets and could stably and continuously release its loaded urokinase. The mouse mesenteric thrombosis model was established to evaluate the thrombolysis effect of the cRGD urokinase liposomes. The results demonstrated that the cRGD liposomes could improve the thrombolytic efficacy by almost 4-fold over free urokinase. In conclusion, the cRGD liposomes encapsulating urokinase had great potential for the clinical treatment of thrombosis.
Related Concept Videos
Stereoisomerism of Cyclic Compounds
Voltammetric Techniques: Cyclic Voltammetry
Cyclic Processes And Isolated Systems
In the case of a non-isolated system, the change in the internal energy is zero only if the process is cyclic. A thermodynamic process is considered cyclic if the system undergoes a series of changes and returns to its initial state.
Consider a cyclic process that returns to its initial state, undergoing a four-step process. The heat transfer along each...
Diels–Alder Reaction Forming Cyclic Products: Stereochemistry
Functional Groups
Functional Groups

